CoChat

Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss

Arias, L, Armadá, F, Donate, J, García-Arumí, J, Giralt, J, Pazos, B, Piñero, A, Martínez, F, Mondéjar, J J, Ortega, I, Zlateva, G, Buggage, R · 2009 · Eye

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Purpose To assess the impact on visual acuity of delays between diagnosis and treatment in patients with subfoveal neovascular age-related macular degeneration (NV-AMD) and to evaluate NV-AMD patients' emotional status before therapy initiation. Methods This retrospective, multicenter, epidemiological study included newly diagnosed NV-AMD patients registered in the Spanish national health system and referred to regional health centers for evaluation/treatment by a retinal specialist from 09/2005 to 03/2006. Records were reviewed and data abstracted at referring physicians' offices (diagnosis visit) and regional health centers (treatment visit). Treatment was at physicians' discretion. The Hospital Anxiety and Depression Scale was administered at the treatment visit (before therapy). Results Median time from the diagnosis to treatment visit was 2.3 months (95% confidence interval: 0.2-10.8 months). Vision loss had progressed at the treatment visit with a doubling in the percentage of patients with a visual acuity of 20/400 or worse (from 12.4 to 24.7%). The decrease in visual acuity from the diagnosis to the treatment visit was highly statistically significant (P Conclusions Delayed treatment of patients newly diagnosed with NV-AMD is associated with substantial visual acuity loss.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.eye.6703053

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

See all 67

Metadata

Authors
Arias, L., Armadá, F., Donate, J., García-Arumí, J., Giralt, J., Pazos, B., Piñero, A., Martínez, F., Mondéjar, J. J., Ortega, I., Zlateva, G., & Buggage, R.
Affiliations
  • Bellvitge University Hospital (ES)
  • Hospital Universitario La Paz (ES)
  • Universitat Autònoma de Barcelona (ES)
  • Hospital Universitario de Valme (ES)
  • Marqués de Valdecilla University Hospital (ES)
  • Pfizer (United States) (US)
Corresponding author
Arias, L
Venue
Eye
Published
2008-01-18
Volume
23
Issue
2
Pages
326-333
ISSN
  • 0078-5334 (ISSN-L)
  • 0950-222X
  • 1476-5454
OpenAlex
W2024615783
Cited by
67
References
23
Citations by year
2026: 2 · 2025: 4 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 4 · 2018: 2 · 2017: 6 · 2016: 4 · 2015: 3 · 2014: 4 · 2013: 12 · 2012: 2
FWCI
4.39
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Eye (publishedVersion)
  • PubMed (publishedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
neovascular age-related macular degeneration, treatment delay, time from diagnosis to treatment, visual acuity loss, depression, anxiety, emotional state, lesion size
MeSH terms
Aged, Aged, 80 and over, Anxiety, Depression, Female, Humans, Macular Degeneration, Male, Retrospective Studies, Time Factors, Vision Disorders, Visual Acuity, Treatment Outcome, Disease Progression, Choroidal Neovascularization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss. https://app.cochat.ai/papers/10.1038/sj.eye.6703053
The paper
Arias, L., Armadá, F., Donate, J., García-Arumí, J., Giralt, J., Pazos, B., Piñero, A., Martínez, F., Mondéjar, J. J., Ortega, I., Zlateva, G., & Buggage, R. (2009). Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss. Eye. https://doi.org/10.1038/sj.eye.6703053

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.